Aeglea BioTherapeutics, Inc. is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood. Its portfolio of products include AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency. AEB1102 is in Phase I clinical trial in oncology. AEB3103 is an enzyme that degrades the amino acids cysteine/cysteine. AEB2109 is an enzyme that degrades the amino acid methionine to target methionine dependent cancers. AEB4104 is an engineered human enzyme to target the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.